- Home
- SANW vs NERV Comparison
SANW vs NERV Comparison
Compare SANW & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANW
- NERV
- Stock Information
- Founded
- SANW 1980
- NERV 2007
- Country
- SANW United States
- NERV United States
- Employees
- SANW N/A
- NERV N/A
- Industry
- SANW Farming/Seeds/Milling
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SANW Consumer Staples
- NERV Health Care
- Exchange
- SANW Nasdaq
- NERV Nasdaq
- Market Cap
- SANW 12.0M
- NERV 12.6M
- IPO Year
- SANW 2010
- NERV 2014
- Fundamental
- Price
- SANW $2.20
- NERV $1.77
- Analyst Decision
- SANW Strong Buy
- NERV Hold
- Analyst Count
- SANW 1
- NERV 1
- Target Price
- SANW $25.00
- NERV $5.00
- AVG Volume (30 Days)
- SANW 73.8K
- NERV 12.2K
- Earning Date
- SANW 05-15-2025
- NERV 08-05-2025
- Dividend Yield
- SANW N/A
- NERV N/A
- EPS Growth
- SANW N/A
- NERV N/A
- EPS
- SANW N/A
- NERV 0.83
- Revenue
- SANW $54,993,808.00
- NERV N/A
- Revenue This Year
- SANW N/A
- NERV N/A
- Revenue Next Year
- SANW $17.19
- NERV N/A
- P/E Ratio
- SANW N/A
- NERV $2.18
- Revenue Growth
- SANW 6.91
- NERV N/A
- 52 Week Low
- SANW $1.99
- NERV $1.15
- 52 Week High
- SANW $11.60
- NERV $3.50
- Technical
- Relative Strength Index (RSI)
- SANW 19.42
- NERV 57.10
- Support Level
- SANW $2.00
- NERV $1.62
- Resistance Level
- SANW $5.37
- NERV $1.83
- Average True Range (ATR)
- SANW 0.39
- NERV 0.09
- MACD
- SANW -0.39
- NERV -0.00
- Stochastic Oscillator
- SANW 5.63
- NERV 64.29
About SANW S&W Seed Company (NV)
S&W Seed Co is a multi-crop, middle-market agricultural company. It is engaged in the breeding, production, and sale of alfalfa seed and sorghum seed. It also has a growing commercial market presence in sunflower and maintains an active stevia development program. The company's seed platform develops and supplies germplasm designed to produce higher yields for farmers globally. Its geographical segments include the United States, Australia, Saudi Arabia, Mexico, South Africa, and other countries. Maximum of revenue is earned from USA following Australia second and Mexico third.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.